Page last updated: 2024-12-06

flunixin meglumine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID) used in veterinary medicine to treat pain and inflammation. It is a derivative of fluoroacetic acid and is synthesized through a multi-step process involving the reaction of 2-fluoro-4-methylaniline with acetic anhydride, followed by a series of transformations and salt formation with meglumine. Flunixin meglumine acts by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, signaling molecules that contribute to inflammation and pain. Its importance lies in its ability to provide effective pain relief and reduce inflammation in various animal species, including horses, cattle, and pigs. It is widely studied to understand its pharmacokinetic properties, therapeutic efficacy, and potential adverse effects in different animal models. Research focuses on optimizing its dosage and administration route for optimal therapeutic outcomes while minimizing potential side effects.'

flunixin meglumine : An organoammonium salt obtained by combining flunixin with one molar equivalent of 1-deoxy-1-(methylamino)-D-glucitol. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine for treatment of horses, cattle and pigs. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID39212
CHEMBL ID1733447
CHEBI ID76144
SCHEMBL ID43691
MeSH IDM0063145

Synonyms (89)

Synonym
AC-6012
MLS002153985
smr000875279
BSPBIO_002558
flunixin meglumine, >=98% (hplc)
einecs 255-836-0
finadyne
d-glucitol, 1-deoxy-1-(methylamino)-, 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-3-pyridinecarboxylate (salt)
banamine (veterinary)
sch 14714 meglumine
flunixin meglumine [usan]
flunixin n-methylglucanine
banamine
1-deoxy-1-(methylamino)-d-glucitol 2-(2-methyl-3-(perfluoromethyl)anilino)nicotinate
2-(alpha(sup 3),alpha(sup 3),alpha(sup 3)-trifluoro-2,3-xylidino)nicotinic acid compound with 1-deoxy-1-(methylamino)-d-glucitol (1:1)
2-((2-methyl-3-(trifluoromethyl)-phenyl)amino)-3-pyridinecarboxylic acid with meglumine compounded
NCGC00180889-01
banamine [vetarynary] (tn)
42461-84-7
flunixin meglumine (usp)
D04216
MLS001333159
flunixin meglumine
sch-14714 meglumine
SPECTRUM1505113
HMS2093I10
flunixin meglumin
nsc759583
nsc-759583
pharmakon1600-01505113
HMS2234K05
chebi:76144 ,
flunixin meglumine salt
CHEMBL1733447
nsc 759583
flumeglumine
8y3jk0jw3u ,
flunixin-s
flunixin meglumine [usan:usp]
unii-8y3jk0jw3u
flunixin meglumine [usp-rs]
2-(.alpha.(sup 3),.alpha.(sup 3),.alpha.(sup 3)-trifluoro-2,3-xylidino)nicotinic acid compound with 1-deoxy-1-(methylamino)-d-glucitol (1:1)
flunixin meglumine salt [mi]
flunixin meglumine [mart.]
flunixin meglumine [usp monograph]
flunixin meglumine [green book]
AKOS015895954
S2108
CCG-213338
HY-B0386
flunixin (meglumine)
SCHEMBL43691
2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}nicotinic acid--1-deoxy-1-(methylamino)-d-glucitol (1/1)
1-deoxy-1-(methylazaniumyl)-d-glucitol 2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}nicotinate
KS-5126
Q-201124
AB00920714_05
AB00920714_06
flunixin meglumine, united states pharmacopeia (usp) reference standard
mfcd01725419
sr-05000001901
SR-05000001901-1
SR-05000001901-3
flunixin meglumine, european pharmacopoeia (ep) reference standard
flunixin meglumine, pharmaceutical secondary standard; certified reference material
(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;2-[2-methyl-3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid
SW196448-3
(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(2-methyl-3-(trifluoromethyl)phenylamino)nicotinate
Q27145782
flunixin meglumine 100 microg/ml in acetonitrile
HMS3884J07
(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)nicotinate
H10204
(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol2-((2-methyl-3-(trifluoromethyl)phenyl)amino)nicotinate
flunixin meglumine (usp-rs)
flunixin meglumine solution
flunazine
flunixin injection-s
banamine, banamine-s
flunixin meglumine (usp monograph)
flunazine-s
flunixin meglumine (usan:usp)
flunixin meglumine (mart.)
banamine (vetarynary)
flunixin meglumine injection
banamine granules
banamine paste
flunixin injection
flunixin meglumine injectable solution

Research Excerpts

Overview

Fluoxin meglumine (FM) is a nonsteroidal anti-inflammatory drug. FM is limited by irritation of the respiratory tract and mucosa in veterinary tissue.

ExcerptReferenceRelevance
"Flunixin meglumine (FM) is a nonsteroidal anti-inflammatory drug limited by irritation of the respiratory tract and mucosa in veterinary tissue. "( Preparation, evaluation, and pharmacokinetics in beagle dogs of a taste-masked flunixin meglumine orally disintegrating tablet prepared using hot-melt extrusion technology and D-optimal mixture design.
Chen, H; Deng, R; Feng, X; He, J; Liang, Q; Wen, X; Wu, L; Xu, Y; Yan, G; Zhang, L, 2022
)
2.39

Effects

Flinixin meglumine (FM) has been demonstrated to delay luteolysis and to support embryonic survival. FM has been reported to induce gastrointestinal lesions in dogs when administered at therapeutic dosages.

ExcerptReferenceRelevance
"Flunixin meglumine (FM) has been demonstrated to delay luteolysis and to support embryonic survival."( Effect of flunixin meglumine and carprofen on pregnancy rates in dairy cattle.
Heuwieser, W; von Krueger, X, 2010
)
1.48
"Flunixin meglumine has been reported to induce gastrointestinal lesions in dogs when administered at therapeutic dosages. "( Effects of flunixin and flunixin plus prednisone on the gastrointestinal tract of dogs.
Curtis, CR; Dow, SW; McChesney, AE; Rosychuk, RA, 1990
)
1.72

Actions

Fluunixin meglumine and AHI-805 inhibit recovery of barrier function in ischaemic-injured equine jejunum in vitro through inhibition of the COX enzymes. Flunixins did not inhibit endogenous PGF2 alpha secretion.

ExcerptReferenceRelevance
"Flunixin meglumine and AHI-805 inhibit recovery of barrier function in ischaemic-injured equine jejunum in vitro through inhibition of the COX enzymes."( The effects of a novel anti-inflammatory compound (AHI-805) on cyclooxygenase enzymes and the recovery of ischaemia injured equine jejunum ex vivo.
Bhatnagar, AS; Blikslager, AT; Bowman, SG; Marshall, JF; Morris, NN; Redding, CD; Skorich, DA, 2011
)
1.81
"Flunixin meglumine (FM; n=10) to inhibit PGF2α secretion or vehicle (n=9) were given intramuscularly at Hours 0, 4, 8, 16, 24, 32, and 40."( Inhibition of prostaglandin biosynthesis during postluteolysis and effects on CL regression, prolactin, and ovulation in heifers.
Beg, MA; Carvalho, GR; Ginther, OJ; Hannan, MA; Khan, FA; Pugliesi, G, 2012
)
1.1
"Flunixin meglumine did not inhibit endogenous PGF2 alpha secretion."( Effect of flunixin meglumine on endogenous prostaglandin F2 alpha secretion during cloprostenol-induced abortion in mares.
Daels, PF; Kindahl, H; Mohammed, HO; Odensvik, K, 1995
)
1.41

Treatment

Flinixin meglumine is used for treatment of equine colic despite evidence of inhibited recovery of mucosal barrier function following small intestinal ischaemic injury. Cows treated with flunixinMeglamine showed significantly less weight-shifting between the rear limbs at 6, 12, and 24 h after treatment.

ExcerptReferenceRelevance
"Flunixin meglumine treatment slightly increased rectal temperature (38.99 vs."( Effects of flunixin meglumine on pyrexia and bioenergetic variables in postparturient dairy cows.
Baumgard, LH; Hill, KL; Shwartz, G; VanBaale, MJ, 2009
)
1.46
"Flunixin meglumine is used for treatment of equine colic despite evidence of inhibited recovery of mucosal barrier function following small intestinal ischaemic injury. "( The effects of a novel anti-inflammatory compound (AHI-805) on cyclooxygenase enzymes and the recovery of ischaemia injured equine jejunum ex vivo.
Bhatnagar, AS; Blikslager, AT; Bowman, SG; Marshall, JF; Morris, NN; Redding, CD; Skorich, DA, 2011
)
1.81
"Flunixin meglumine treatment suppressed serum PGFM concentrations in control and ACTH-treated cows."( Effects of adrenocorticotropic hormone and flunixin meglumine on pregnancy retention in beef cows.
Geary, TW, 2012
)
1.36
"Flunixin meglumine treated animals' demonstrated reduced expression of CD1 in comparison to the LPS-stimulated swine at 24 and 48 h post LPS-stimulation."( In vivo characterization of inflammatory biomarkers in swine and the impact of flunixin meglumine administration.
Chiesa, OA; Deaver, C; Esparza, J; Jones, YL; Kenyon, E; Lancaster, V; Myers, MJ; Peters, SM; Screven, R; Stubbs, JT; Wiesenfeld, PL; Yancy, H; Yang, M, 2012
)
1.33
"Flunixin meglumine treatment did not alter cardiac indices or tissue blood flows significantly."( Effects of flunixin meglumine on dogs with experimental gastric dilatation-volvulus.
Bottoms, GD; Davidson, JR; Kazacos, EA; Lantz, GC; Salisbury, SK,
)
1.24
"Flunixin meglumine treatment produced significant (P less than 0.05) reductions in milk TxB2 and plasma 15-keto-13,14-dihydro-PGF2 alpha concentrations."( Endotoxin-induced bovine mastitis: arachidonic acid metabolites in milk and plasma and effect of flunixin meglumine.
Anderson, KL; Davis, LE; Gustafsson, BK; Kindahl, H; Smith, AR, 1986
)
1.21
"Flunixin meglumine treatment prevented systemic hypotension and hypoxemia, reversed the early but not the late stages of portal hypertension, and decreased E coli concentrations in the lungs."( Escherichia coli-induced lung and liver dysfunction in dogs: effects of flunixin meglumine treatment.
Hardie, EM; Rakich, PM; Rawlings, CA; Shotts, EB; Waltman, DW, 1987
)
1.23
"Cows treated with flunixin meglumine showed significantly less weight-shifting between the rear limbs at 6, 12, and 24 h after treatment compared with saline-treated controls, providing evidence that flunixin meglumine alleviates lameness-associated pain."( Short communication: Behavioral evaluation of the analgesic effect of flunixin meglumine in lame dairy cows.
Manning, BH; Tena, JK; Wagner, SA; Young, JM, 2017
)
1.01
"Eyes treated with flunixin meglumine contained less 6-keto PGF1alpha than did control eyes."( Effect of flunixin meglumine on prostacyclin accumulation in the equine eye.
Cooley, PL; Laratta, LJ; Milvae, R; Riis, RC, 1984
)
0.99
"Cows treated with flunixin meglumine had increased rumen motility and decreased rectal temperature during the same period, compared with all other cows."( Effects of two anti-inflammatory drugs on physiologic variables and milk production in cows with endotoxin-induced mastitis.
Apley, MD; Wagner, SA, 2004
)
0.65
"Dogs treated with flunixin meglumine had longer survival times (9-24 hr), lower body temperatures, higher stroke indexes, higher mean arterial pressures, and higher blood pH values than untreated dogs."( Canine septic peritonitis: treatment with flunixin meglumine.
Hardie, EM; Kolata, RJ; Rawlings, CA, 1983
)
0.85
"Treatment with flunixin meglumine (group 3 ponies) exerted selective microvascular actions which helped to reverse endotoxin-induced changes."( Endotoxin-induced hemodynamic changes in ponies: effects of flunixin meglumine.
Bottoms, GD; Fessler, JF; Frauenfelder, HC; Moore, AB; Roesel, OF, 1981
)
0.84
"Dogs treated with flunixin meglumine plus prednisone developed the earliest and most severe lesions; lesion scores in group-2 dogs were higher than those in group-1 dogs."( Effects of flunixin and flunixin plus prednisone on the gastrointestinal tract of dogs.
Curtis, CR; Dow, SW; McChesney, AE; Rosychuk, RA, 1990
)
0.6
"Treatment with flunixin meglumine or flurbiprofen almost completely abolished the febrile response during the first nine hours after infection, and the decrease in rumen motility was less pronounced in the treated animals."( Flunixin meglumine and flurbiprofen in cows with experimental Escherichia coli mastitis.
Brand, A; Lohuis, JA; Van Leeuwen, W; Van Miert, AS; Verheijden, JH, 1989
)
2.06
"Pretreatment with flunixin meglumine (1 mg/kg of body weight) prevented most of the endotoxin-induced changes and correlated with a significant decrease in plasma TxB2 and 6-keto PGF1 alpha concentrations, compared with concentrations in nontreated horses (ie, pretreated with saline solution)."( Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor.
Hardee, GE; Hardee, MM; Moore, JN, 1986
)
0.82
"Treatment (flunixin meglumine, 1.1 mg/kg of body weight) was given to 6 of the 12 ponies 1 minute before an IV injection of Escherichia coli endotoxin (100 micrograms/kg of body weight, LD100)."( Effects of flunixin meglumine on blood pressure and fluid compartment volume changes in ponies given endotoxin.
Bottoms, GD; Dunkle, NJ; Fessler, JF; Knox, K; Roesel, OF, 1985
)
1.03
"Treatment with flunixin meglumine prevented the endotoxin-induced release of these cyclooxygenase products to levels below those observed in control cells."( Endotoxin-induced eicosanoid production by equine vascular endothelial cells and neutrophils.
Bottoms, GD; Fessler, JF; Johnson, MA; Lamar, CH; Turek, JJ, 1985
)
0.61

Toxicity

To evaluate the ability of atropine sulfate, butylscopolammonium bromide combined with metamizole sodium, and flunixin meglumine to ameliorate the clinical adverse effects of imidocarb dipropionate in horses.

ExcerptReferenceRelevance
"To evaluate adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs."( Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007
)
0.79
"Carprofen induced the lowest frequency of gastrointestinal adverse effects, followed by meloxicam."( Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007
)
0.56
"In this study, we elucidated the difference in nonsteroidal anti-inflammatory drug sensitivities between young and adult cats on therapeutic and adverse effects."( Therapeutic and adverse effects of flunixin-meglumine in adult and young cats.
Hikasa, Y; Satoh, H; Takata, K, 2011
)
0.37
"To evaluate the ability of atropine sulfate, butylscopolammonium bromide combined with metamizole sodium, and flunixin meglumine to ameliorate the clinical adverse effects of imidocarb dipropionate in horses."( Evaluation of the use of atropine sulfate, a combination of butylscopolammonium bromide and metamizole sodium, and flunixin meglumine to ameliorate clinical adverse effects of imidocarb dipropionate in horses.
Abutarbush, SM; Al-Majali, AM; Alfaqeeh, SM; Mustafa, G; Qura'n, L, 2013
)
0.81
"Imidocarb dipropionate use in the control group was associated with serious adverse effects including signs of abdominal pain (4/7 horses) and diarrhea (2/7)."( Evaluation of the use of atropine sulfate, a combination of butylscopolammonium bromide and metamizole sodium, and flunixin meglumine to ameliorate clinical adverse effects of imidocarb dipropionate in horses.
Abutarbush, SM; Al-Majali, AM; Alfaqeeh, SM; Mustafa, G; Qura'n, L, 2013
)
0.6
"A combination of butylscopolammonium bromide and metamizole sodium may be useful to ameliorate the adverse effects of imidocarb dipropionate in horses, although group size was small and significant differences from the control group were not found."( Evaluation of the use of atropine sulfate, a combination of butylscopolammonium bromide and metamizole sodium, and flunixin meglumine to ameliorate clinical adverse effects of imidocarb dipropionate in horses.
Abutarbush, SM; Al-Majali, AM; Alfaqeeh, SM; Mustafa, G; Qura'n, L, 2013
)
0.6

Pharmacokinetics

To examine pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs following simultaneously administered SC injections of these drugs. A standard dose of fl Unixin was administered intravenously to eight horses of each breed, and three-compartmental analysis was used to compare pharmacokinetics parameters.

ExcerptReferenceRelevance
" Significant difference was not apparent in the pharmacokinetic values of flunixin meglumine with and without concurrent probenecid administration."( Effect of probenecid on the pharmacokinetics of flunixin meglumine and phenylbutazone in healthy mares.
Brown, MP; Gronwall, R; Merritt, K; Zertuche, JM, 1992
)
0.77
" Five pharmacodynamic end-points were regularly measured after test article injection using standardized procedures: local skin temperature, stride length, the rest angle flexion and the maximal carpal flexion of the injured leg and circumference of the inflamed joint."( Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling.
Alvinerie, M; Autefage, A; Legrand, C; Toutain, PL, 1994
)
0.52
"There are relatively few non-steroidal anti-inflammatory drugs (NSAIDs) for which basic pharmacokinetic and toxicological data are available in the cat."( Flunixin in the cat: a pharmacodynamic, pharmacokinetic and toxicological study.
Jefferies, R; Lees, P; Taylor, PM; Winnard, JG,
)
0.13
"Age and species reportedly affect the pharmacokinetic variables of nonsteroidal anti-inflammatory drugs."( Pharmacokinetics of and serum thromboxane suppression by flunixin meglumine in healthy foals during the first month of life.
Ashcraft, SM; Sams, RA; Semrad, SD, 1993
)
0.53
" Pharmacokinetic variables calculated for each drug when given alone and in combination were similar to those reported."( Effects of concurrent administration of phenylbutazone and flunixin meglumine on pharmacokinetic variables and in vitro generation of thromboxane B2 in mares.
Ashcraft, SM; Harris, ON; Sams, RA; Semrad, SD, 1993
)
0.53
" Pharmacokinetic variables were calculated using statistical moment methods."( Pharmacokinetics of flunixin and its effect on prostaglandin F2 alpha metabolite concentrations after oral and intravenous administration in heifers.
Odensvik, K, 1995
)
0.29
" Concentration versus time profiles were analyzed according to standard pharmacokinetic techniques."( Pharmacokinetics of flunixin meglumine in healthy foals less than twenty-four hours old.
Crisman, MV; Sams, RA; Wilcke, JR, 1996
)
0.62
" Significant differences were not found between horses and mules for any pharmacokinetic variable."( Pharmacokinetics of flunixin meglumine in donkeys, mules, and horses.
Coakley, M; Matthews, NS; Mealey, KL; Peck, KE; Taylor, TS, 1999
)
0.63
" Unusual pharmacokinetic profiles were obtained, including high binding percentage with plasma protein (> 99%), a short elimination half-life (< 4 hr) and a relatively large Vd-area (0."( Possible active transport mechanism in pharmacokinetics of flunixin-meglumin in rabbits.
Horii, Y; Ikenaga, N; Kokue, E; Miyazaki, Y; Shimoda, M, 2001
)
0.31
"To examine pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs following simultaneously administered SC injections of these drugs."( Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs.
Mizuno, Y; Ogata, T; Ogino, T; Takahashi, Y, 2005
)
0.87
"5, 2, 3, 5, 8, 12, and 24 hours following SC injections, and pharmacokinetic parameters of flunixin and enrofloxacin were calculated from plasma drug concentrations."( Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs.
Mizuno, Y; Ogata, T; Ogino, T; Takahashi, Y, 2005
)
0.61
"Significant increases in the area under the curve (32%) and in the elimination half-life (29%) and a significant decrease (23%) in the elimination rate constant from the central compartment of flunixin were found following coadministration with enrofloxacin, compared with administration of flunixin alone."( Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs.
Mizuno, Y; Ogata, T; Ogino, T; Takahashi, Y, 2005
)
0.61
"62 L/(h kg)), and a relatively short elimination half-life (1."( Pharmacokinetics of flunixin after intravenous administration in healthy and endotoxaemic rabbits.
Elmas, M; Karabacak, A; Uney, K; Yazar, E, 2006
)
0.33
"We examined the pharmacokinetic interactions of enrofloxacin and flunixin in male ICR mice that were subcutaneously (SC) administered with both or either one of the drugs."( Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in ICR mice.
Arai, T; Ogino, T, 2007
)
0.62
" There is a need for a pharmacokinetic modeling technique that can predict the consequences of possible drug interactions."( A physiologically based pharmacokinetic model linking plasma protein binding interactions with drug disposition.
Baynes, RE; Buur, JL; Riviere, JE; Smith, GW, 2009
)
0.35
" Our data indicate that multiple administration of flunixin did not alter significantly the parent drug and its metabolite concentrations in plasma, however may cause some small changes in pharmacokinetic parameters."( Pharmacokinetics of flunixin in mature heifers following multiple intravenous administration.
Chrostowska, M; Grabowski, T; Jaroszewski, J; Jedziniak, P; Markiewicz, W; Szprengier-Juszkiewicz, T, 2008
)
0.35
" Both acute hepatic and renal failure resulted in significantly increased area under the curve (AUC), prolonged elimination half-life (t(1/2β)), and reduced total body clearance (Cl(tot)) compared with respective controls (P<0."( Effects of acute hepatic and renal failure on pharmacokinetics of flunixin meglumine in rats.
Hwang, YH; Yun, HI, 2011
)
0.61
" A standard dose of flunixin meglumine was administered intravenously to eight horses of each breed, and three-compartmental analysis was used to compare pharmacokinetic parameters between breed groups."( Effect of body weight on the pharmacokinetics of flunixin meglumine in miniature horses and quarter horses.
Lee, CD; Maxwell, LK, 2014
)
0.98
" Plasma samples collected up to 48 hours post-administration were analyzed by high pressure liquid chromatography and mass spectrometry (HPLC-MS) followed by non-compartmental pharmacokinetic analysis."( Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration.
Coetzee, JF; Johnson, AK; Karriker, LA; Kukanich, B; Millman, ST; Pairis-Garcia, MD; Sander, S; Stalder, KJ; Wulf, L, 2013
)
0.71
" Lower F and Cmax of PO-FM in comparison to IM-FM suggest that PO-FM is less likely to be an effective therapeutic administration route."( Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration.
Coetzee, JF; Johnson, AK; Karriker, LA; Kukanich, B; Millman, ST; Pairis-Garcia, MD; Sander, S; Stalder, KJ; Wulf, L, 2013
)
0.71
" Within-drug and metabolite analysis of pharmacokinetic parameters included fixed effects of drug administration date, sex and breed of sire."( The effect of breed and sex on sulfamethazine, enrofloxacin, fenbendazole and flunixin meglumine pharmacokinetic parameters in swine.
Ashwell, MS; Baynes, RE; Bellis, B; Brooks, JD; Howard, JT; Maltecca, C; O'Nan, AT; Routh, P; Yeatts, JL, 2014
)
0.63
" For each administration route, pharmacokinetic parameters were determined by noncompartmental methods and compared between the 2 ages."( Effect of age on the pharmacokinetics and pharmacodynamics of flunixin meglumine following intravenous and transdermal administration to Holstein calves.
Coetzee, JF; Gorden, PJ; Kleinhenz, MD; KuKanich, B; Perkins, S; Rajewski, SM; Smith, JS; Van Engen, NK; Walsh, P, 2018
)
0.72
" Plasma half-life of flunixin was significantly longer in PAIN (10."( The impact of pain on the pharmacokinetics of transdermal flunixin meglumine administered at the time of cautery dehorning in Holstein calves.
Coetzee, JF; Gorden, PJ; Kleinhenz, KE; Kleinhenz, MD; Kukanich, B; Rajewski, SM; Van Engen, NK; Walsh, P, 2018
)
0.73
" One of the tools is physiologically based pharmacokinetic (PBPK) modeling, which is a mechanistic-based approach that can be used to predict tissue residues and WDIs."( Integration of Food Animal Residue Avoidance Databank (FARAD) empirical methods for drug withdrawal interval determination with a mechanistic population-based interactive physiologically based pharmacokinetic (iPBPK) modeling platform: example for flunixi
Baynes, RE; Cheng, YH; Chittenden, JT; Davis, JL; Li, M; Lin, Z; Riviere, JE; Tell, LA; Vickroy, TW, 2019
)
0.51
" Noncompartmental analysis was used to estimate pharmacokinetic parameters for the MLK group."( Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy.
Coetzee, JF; Hartnack, AK; Kleinhenz, MD; Lakritz, J; Niehaus, AJ, 2020
)
0.56
"During the CRI of the MLK solution, steady-state serum concentrations were achieved for lidocaine and ketamine, but not morphine, likely owing to the fairly long half-life of morphine."( Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy.
Coetzee, JF; Hartnack, AK; Kleinhenz, MD; Lakritz, J; Niehaus, AJ, 2020
)
0.56
" A common practice in racetrack medicine in the USA is to administer the two drugs within close proximity (24 hours apart) of each other, raising the concern of pharmacokinetic interactions and enhanced anti-inflammatory effects."( Pharmacokinetics and anti-inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses.
Arthur, RM; Baden, RW; Kass, PH; Knych, HK; McKemie, DS; Seminoff, K, 2021
)
0.87
" Concentrations of FM, PBZ and eicosanoids were measured using LC-MS/MS and noncompartmental pharmacokinetic analysis performed on concentration data."( Pharmacokinetics and anti-inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses.
Arthur, RM; Baden, RW; Kass, PH; Knych, HK; McKemie, DS; Seminoff, K, 2021
)
0.87
" No other differences in pharmacokinetic parameters were noted between groups."( Pharmacokinetics and anti-inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses.
Arthur, RM; Baden, RW; Kass, PH; Knych, HK; McKemie, DS; Seminoff, K, 2021
)
0.87
" Finally, a pharmacokinetic study proved that the main pharmacokinetic parameters of FM ODT were not significantly different from those of commercial granules, which indicated that these formulations had similar pharmacokinetic behaviours in beagles."( Preparation, evaluation, and pharmacokinetics in beagle dogs of a taste-masked flunixin meglumine orally disintegrating tablet prepared using hot-melt extrusion technology and D-optimal mixture design.
Chen, H; Deng, R; Feng, X; He, J; Liang, Q; Wen, X; Wu, L; Xu, Y; Yan, G; Zhang, L, 2022
)
0.95

Compound-Compound Interactions

ExcerptReferenceRelevance
") administration of ceftiofur was used for five days in combination with flunixin for three days."( Treatment of dairy cows with PGF2α or NSAID, in combination with antibiotics, in cases of postpartum uterine inflammation.
Jeremejeva, J; Kask, K; Orro, T; Waldmann, A, 2012
)
0.38
"Twelve Thoroughbred exercised horses received 500 mg FM IV alone or in combination with 2 g of IV PBZ 24 hours later."( Pharmacokinetics and anti-inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses.
Arthur, RM; Baden, RW; Kass, PH; Knych, HK; McKemie, DS; Seminoff, K, 2021
)
0.87

Bioavailability

ExcerptReferenceRelevance
" Bioavailability after IM dosing gave a mean +/- SD (n = 5) of 76."( Pharmacokinetics of flunixin meglumine in lactating cattle after single and multiple intramuscular and intravenous administrations.
Anderson, KL; Bass, VD; Davis, LE; Neff-Davis, CA, 1990
)
0.6
" Following intramuscular injection flunixin is rapidly and well absorbed from the injection site."( The pharmacokinetics of flunixin meglumine in the sheep.
McKellar, QA; Nolan, AM; Welsh, EM, 1993
)
0.59
" Mean bioavailability of the oral drug was 71."( Disposition of flunixin meglumine injectable preparation administered orally to healthy horses.
Pellegrini-Masini, A; Poppenga, RH; Sweeney, RW, 2004
)
0.68
" In comparison, bioavailability (F) for PO administration was 22% (range: 11-44%) compared to IM F at 76% (range: 54-92%)."( Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration.
Coetzee, JF; Johnson, AK; Karriker, LA; Kukanich, B; Millman, ST; Pairis-Garcia, MD; Sander, S; Stalder, KJ; Wulf, L, 2013
)
0.71
"Relative bioavailability of meloxicam and flunixin meglumine were reduced when compounded with ID in the same bottle and administered to piglets."( Pharmacokinetics of combined administration of iron dextran with meloxicam or flunixin meglumine in piglets.
Enouri, SS; Friendship, RM; Gu, Y; Johnson, RJ; O'Sullivan, TL; Ramkissoon, S, 2022
)
1.21

Dosage Studied

Flunixin meglumine at the 25-mg/kg dose provided analgesic relief at the latest time point during etomidate dosage and at all time points during benzocaine dosage. The major clinical abnormality was diarrhea, but the incidence was not related to the dosage of flunix in foals.

ExcerptRelevanceReference
" Bioavailability after IM dosing gave a mean +/- SD (n = 5) of 76."( Pharmacokinetics of flunixin meglumine in lactating cattle after single and multiple intramuscular and intravenous administrations.
Anderson, KL; Bass, VD; Davis, LE; Neff-Davis, CA, 1990
)
0.6
" The efficacy of this drug was not improved by increasing the dosage to two or three times the recommended level."( The effect of anti-inflammatory agents on the clinical expression of bovine ephemeral fever.
St George, TD; Uren, MF; Zakrzewski, H, 1989
)
0.28
" The major clinical abnormality was diarrhea, but the incidence was not related to the dosage of flunixin meglumine administered."( Clinical and pathological effects of flunixin meglumine administration to neonatal foals.
Carrick, JB; Middleton, DM; Naylor, JM; Papich, MG; Townsend, HG, 1989
)
0.77
"10 micrograms/ml from 24 hours after drug administration at all dosage levels."( Flunixin pharmacokinetics and serum thromboxane inhibition in the dog.
Bogan, JA; Galbraith, EA; Hooke, RE; Lees, P; McKellar, QA; Russell, CS, 1989
)
0.28
" Within the dosage range studied, linear pharmacokinetics were achieved."( Flunixin meglumine given in small doses: pharmacokinetics and prostaglandin inhibition in healthy horses.
Hardee, GE; Hardee, MM; Moore, JN; Semrad, SD, 1985
)
1.71
" It is concluded that PK/PD is a tool of potential value for the preclinical screening of a dosage regimen."( Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling.
Alvinerie, M; Autefage, A; Legrand, C; Toutain, PL, 1994
)
0.52
" Indwelling catheters were placed on the day preceding the first and last flunixin doses and 2 ml blood samples were taken for flunixin and thromboxane B2 (TXB2) assay before dosing and at 1, 2, 3, 5, 7, and 24 h after the first and the last doses of flunixin."( Flunixin in the cat: a pharmacodynamic, pharmacokinetic and toxicological study.
Jefferies, R; Lees, P; Taylor, PM; Winnard, JG,
)
0.13
" The study showed that it was not possible to affect the time period to completed uterine involution, not even when a very intensive drug dosage was used."( The effect of intensive flunixin treatment during the postpartum period in the bovine.
Fredriksson, G; Odensvik, K, 1993
)
0.29
" The results indicate that oral dosing of flunixin, in the form of granules, can be an alternative to intravenous administration for therapeutic use in cattle."( Pharmacokinetics of flunixin and its effect on prostaglandin F2 alpha metabolite concentrations after oral and intravenous administration in heifers.
Odensvik, K, 1995
)
0.29
"Flunixin meglumine at a dosage of 500 mg/animal, administered IV every 8 hours, is ineffective in modulating uterine PGF2 alpha secretion during cloprostenol-induced abortion."( Effect of flunixin meglumine on endogenous prostaglandin F2 alpha secretion during cloprostenol-induced abortion in mares.
Daels, PF; Kindahl, H; Mohammed, HO; Odensvik, K, 1995
)
2.14
"To titrate a clinically effective eltenac dosage (0."( Determination of an effective dose of eltenac and its comparison with that of flunixin meglumine in horses after experimentally induced carpitis.
Hamm, D; Johnson, JC; Katz, T; Lockwood, PW; Thompson, KC; Turchi, P, 1997
)
0.53
"Under conditions of this study, a dosage plateau for eltenac was determined (0."( Determination of an effective dose of eltenac and its comparison with that of flunixin meglumine in horses after experimentally induced carpitis.
Hamm, D; Johnson, JC; Katz, T; Lockwood, PW; Thompson, KC; Turchi, P, 1997
)
0.53
" Three dosing regimes were used; twice (n = 2), thrice (n = 4) and four times daily (n = 6)."( The effect on luteolysis by intensive oral administration of flunixin granules in heifers.
Gustafsson, H; Kindahl, H; Odensvik, K, 1998
)
0.3
"14 horses were treated with each dosage of gentamicin (i."( Drug disposition and dosage determination of once daily administration of gentamicin sulfate in horses after abdominal surgery.
Papich, MG; Redding, WR; Tudor, RA, 1999
)
0.3
" Mean pharmacokinetic variables for gentamicin administration at a high or low dosage (i."( Drug disposition and dosage determination of once daily administration of gentamicin sulfate in horses after abdominal surgery.
Papich, MG; Redding, WR; Tudor, RA, 1999
)
0.3
" Consequently, flunixin meglumine dosing regimens used in horses may be inappropriate for use in donkeys."( Pharmacokinetics of flunixin meglumine in donkeys, mules, and horses.
Coakley, M; Matthews, NS; Mealey, KL; Peck, KE; Taylor, TS, 1999
)
0.98
" Ultimately it could be used in the design of dosing regimens and in the protection of the food supply through prediction and minimization of tissue residues."( A physiologically based pharmacokinetic model linking plasma protein binding interactions with drug disposition.
Baynes, RE; Buur, JL; Riviere, JE; Smith, GW, 2009
)
0.35
" Neither flunixin meglumine nor carprofen improved conception rates to first service in dairy cattle in the dosage and administration schedule tested."( Effect of flunixin meglumine and carprofen on pregnancy rates in dairy cattle.
Heuwieser, W; von Krueger, X, 2010
)
1.18
" Our results indicate that the use of meloxicam or flunixin in accordance with the recommended dosage regimen in cattle do not have a clinically significant influence on apoptosis of peripheral blood T cells."( Evaluation of the influence of meloxicam and flunixin meglumine on the apoptosis of peripheral blood CD4+ and CD8+ T cells in calves.
Jakubowski, P; Jaroszewski, JJ; Markiewicz, W; Maślanka, T, 2010
)
0.62
" Flunixin meglumine at the given dosage (2."( Effects of buprenorphine, meloxicam, and flunixin meglumine as postoperative analgesia in mice.
Blankenship-Paris, TL; Clark, JA; Goulding, DR; King-Herbert, AP; Kissling, GE; Travlos, GS; Tubbs, JT, 2011
)
1.55
" Regardless of dosage (1."( Effects of adrenocorticotropic hormone and flunixin meglumine on pregnancy retention in beef cows.
Geary, TW, 2012
)
0.64
" Despite the substantial disparity in body size between miniature horses and light-breed horses, there are no studies investigating appropriate dosing of any veterinary drug in miniature horses."( Effect of body weight on the pharmacokinetics of flunixin meglumine in miniature horses and quarter horses.
Lee, CD; Maxwell, LK, 2014
)
0.66
" Flunixin meglumine at the 25-mg/kg dose provided analgesic relief at the latest time point during etomidate dosage and at all time points during benzocaine dosage, but further characterization is warranted regarding long-term or repeated analgesic administration."( Comparison of Etomidate, Benzocaine, and MS222 Anesthesia with and without Subsequent Flunixin Meglumine Analgesia in African Clawed Frogs (
Carroll, GL; Elliott, JJ; Jeffery, ND; Smith, BD; Taylor, MC; Vail, KJ; Vemulapalli, TH, 2018
)
1.61
" Kinetic analyses of MLK infusions in cattle are necessary to establish optimal dosing protocols."( Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy.
Coetzee, JF; Hartnack, AK; Kleinhenz, MD; Lakritz, J; Niehaus, AJ, 2020
)
0.56
" Levofloxacin, with an alteration in the dosage regimen, can be used effectively with tolfenamic acid and flunixin meglumine for the therapy of infections and inflammatory conditions in sheep."( Influences of tolfenamic acid and flunixin meglumine on the disposition kinetics of levofloxacin in sheep.
Cetin, G; Corum, O; Durna Corum, D; Eser Faki, H; Ider, M; Uney, K; Yildiz, R, 2020
)
1.05
" Concentrations were adapted to comparable relations of the recommended dosage for systemic application."( Nonsteroidal anti-inflammatory drugs affect the mammary epithelial barrier during inflammation.
Bruckmaier, RM; Sintes, GF; Wellnitz, O, 2020
)
0.56
"This study was designed to determine the effect of PPG and/or flunixin meglumine on SAA response when used at clinical dosing regimens in healthy adult horses."( Effect of Procaine Penicillin G and Flunixin Meglumine on Serum Amyloid A Response in Healthy Adult Horses.
Nottle, BF; Pusterla, N; Trsan, J, 2023
)
1.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitorA compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organoammonium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency19.01150.007215.758889.3584AID588342
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID504466
gemininHomo sapiens (human)Potency1.25890.004611.374133.4983AID624297
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 alphaHomo sapiens (human)AC50300.00000.013529.7434171.7000AID463203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID558037Cytotoxicity against human SVG-A cells2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID558029Antiviral activity against JC polyomavirus M1/SVEdelta infected in human SVG-A cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID558036Therapeutic index, ratio of TC50 for JC polyomavirus M1/SVEdelta infected human SVG-A cells to EC50 for JC polyomavirus M1/SVEdelta2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (415)

TimeframeStudies, This Drug (%)All Drugs %
pre-199065 (15.66)18.7374
1990's100 (24.10)18.2507
2000's83 (20.00)29.6817
2010's130 (31.33)24.3611
2020's37 (8.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.28 (24.57)
Research Supply Index6.25 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index156.73 (26.88)
Search Engine Supply Index2.44 (0.95)

This Compound (73.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials91 (21.31%)5.53%
Reviews4 (0.94%)6.00%
Case Studies27 (6.32%)4.05%
Observational0 (0.00%)0.25%
Other305 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]